Andecaliximab

N/A

Report date: 2025/02/06 14:52:09

Base Information

Drug NameAndecaliximab
Drug Alias NameGS-5745
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMatrix metalloproteinase 9 inhibitors
TargetsMatrix metalloproteinase 9
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsOssification, HeterotopicSpinal Cord Injuries +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesAshibio Inc
Inactive CompaniesGilead Sciences Inc
Active IndicationsOssification, HeterotopicSpinal Cord InjuriesMyositis Ossificans
Inactive IndicationsGastroesophageal Junction NeoplasmsPulmonary Disease, Chronic ObstructiveCystic Fibrosis +[12] 

Other Information

ATC CodeN/A
Related LinksN/A